NCT06900595View on ClinicalTrials.gov

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 2, 2029

Study Completion Date

June 2, 2029

Conditions
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical CarcinomaStage III Adrenal Cortical Carcinoma AJCC v8Stage IV Adrenal Cortical Carcinoma AJCC v8Unresectable Adrenal Cortical Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cabozantinib

Given PO

BIOLOGICAL

Cemiplimab

Given IV

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH